WORX
WORX
SCWorx Corp.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $768.9K ▲ | $542.84K ▲ | $-749.18K ▲ | -97.44% ▲ | $-0.71 ▲ | $-614.03K ▼ |
| Q3-2025 | $705.8K ▲ | $390.78K ▼ | $-1.31M ▲ | -185.96% ▲ | $-2.25 ▲ | $2.29M ▲ |
| Q2-2025 | $682.63K ▼ | $473.94K ▲ | $-1.91M ▼ | -279.23% ▼ | $-6.9 ▼ | $-371.63K ▼ |
| Q1-2025 | $720.3K ▲ | $470.86K ▼ | $-476.3K ▼ | -66.13% ▼ | $-3.75 ▼ | $-334K ▼ |
| Q4-2024 | $675.75K | $538.77K | $-195.29K | -28.9% | $-1.95 | $-152.92K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $1.64M ▲ | $7.9M ▲ | $743.6K ▼ | $7.15M ▲ |
| Q3-2025 | $684.29K ▲ | $7.18M ▲ | $1.18M ▼ | $6M ▲ |
| Q2-2025 | $340.21K ▼ | $6.65M ▼ | $1.2M ▼ | $5.45M ▼ |
| Q1-2025 | $1.07M ▲ | $7.16M ▲ | $1.56M ▼ | $5.59M ▲ |
| Q4-2024 | $106.65K | $6.35M | $1.86M | $4.49M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-749.18K ▲ | $-129.08K ▲ | $-30.64K ▼ | $1.12M ▲ | $960.14K ▲ | $-139.7K ▲ |
| Q3-2025 | $-1.31M ▲ | $-358.08K ▲ | $0 | $702.17K ▲ | $344.09K ▲ | $-358.08K ▲ |
| Q2-2025 | $-1.91M ▼ | $-651.83K ▼ | $0 | $-80.37K ▼ | $-732.21K ▼ | $-651.83K ▼ |
| Q1-2025 | $-476.3K ▼ | $-404.62K ▼ | $0 | $1.37M ▲ | $965.76K ▲ | $-404.62K ▼ |
| Q4-2024 | $-195.29K | $-134.43K | $0 | $153.42K | $18.99K | $-134.43K |
Revenue by Products
| Product | Q1-2018 | Q2-2018 |
|---|---|---|
Athlete Management | $0 ▲ | $0 ▲ |
Corporate Segment | $0 ▲ | $0 ▲ |
Promotion Segment | $0 ▲ | $0 ▲ |
Ticket Service Segment | $0 ▲ | $0 ▲ |
5-Year Trend Analysis
A comprehensive look at SCWorx Corp.'s financial evolution and strategic trajectory over the past five years.
Key positives include a specialized SaaS offering that targets a real and costly pain point for hospitals—data fragmentation and supply chain inefficiency. The company demonstrates a workable gross margin structure, strong short-term liquidity, low traditional debt, and a net cash position. Its product strategy, centered on a comprehensive, interoperable data platform with modular components, provides a clear narrative and potential for sticky customer relationships. These elements together give SCWorx a foundation for potential growth if it can execute commercially and operationally.
The most important risks are financial: substantial operating and net losses, negative cash flow from operations, and reliance on external financing to grow or even maintain operations. Deeply negative retained earnings and an asset base dominated by goodwill and other intangibles highlight a history of losses and potential vulnerability to future write-downs. Competitive risks are also significant, given the presence of much larger healthcare IT players and the company’s small scale and limited brand recognition. If revenue growth does not accelerate or costs are not meaningfully reduced, the current model may prove difficult to sustain over time.
Looking ahead, SCWorx’s outlook hinges on its ability to translate its specialized technology and data platform into a broader, more profitable customer base before financial flexibility tightens. The strong liquidity position buys some time, but ongoing cash burn and high financing costs create pressure to show operational improvement. In a favorable scenario, increased adoption, better cost control, and deeper partnerships could gradually move the company toward a self-sustaining model. In a less favorable scenario, continued losses and competitive headwinds could force strategic changes, restructurings, or additional capital raises under potentially less attractive terms. Overall, the future path remains uncertain and will be driven primarily by execution, customer traction, and cost discipline.
About SCWorx Corp.
https://www.scworx.comSCWorx Corp. develops and markets health care information technology solutions and related services to improve healthcare processes and information flow within hospitals and other healthcare facilities in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $768.9K ▲ | $542.84K ▲ | $-749.18K ▲ | -97.44% ▲ | $-0.71 ▲ | $-614.03K ▼ |
| Q3-2025 | $705.8K ▲ | $390.78K ▼ | $-1.31M ▲ | -185.96% ▲ | $-2.25 ▲ | $2.29M ▲ |
| Q2-2025 | $682.63K ▼ | $473.94K ▲ | $-1.91M ▼ | -279.23% ▼ | $-6.9 ▼ | $-371.63K ▼ |
| Q1-2025 | $720.3K ▲ | $470.86K ▼ | $-476.3K ▼ | -66.13% ▼ | $-3.75 ▼ | $-334K ▼ |
| Q4-2024 | $675.75K | $538.77K | $-195.29K | -28.9% | $-1.95 | $-152.92K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $1.64M ▲ | $7.9M ▲ | $743.6K ▼ | $7.15M ▲ |
| Q3-2025 | $684.29K ▲ | $7.18M ▲ | $1.18M ▼ | $6M ▲ |
| Q2-2025 | $340.21K ▼ | $6.65M ▼ | $1.2M ▼ | $5.45M ▼ |
| Q1-2025 | $1.07M ▲ | $7.16M ▲ | $1.56M ▼ | $5.59M ▲ |
| Q4-2024 | $106.65K | $6.35M | $1.86M | $4.49M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-749.18K ▲ | $-129.08K ▲ | $-30.64K ▼ | $1.12M ▲ | $960.14K ▲ | $-139.7K ▲ |
| Q3-2025 | $-1.31M ▲ | $-358.08K ▲ | $0 | $702.17K ▲ | $344.09K ▲ | $-358.08K ▲ |
| Q2-2025 | $-1.91M ▼ | $-651.83K ▼ | $0 | $-80.37K ▼ | $-732.21K ▼ | $-651.83K ▼ |
| Q1-2025 | $-476.3K ▼ | $-404.62K ▼ | $0 | $1.37M ▲ | $965.76K ▲ | $-404.62K ▼ |
| Q4-2024 | $-195.29K | $-134.43K | $0 | $153.42K | $18.99K | $-134.43K |
Revenue by Products
| Product | Q1-2018 | Q2-2018 |
|---|---|---|
Athlete Management | $0 ▲ | $0 ▲ |
Corporate Segment | $0 ▲ | $0 ▲ |
Promotion Segment | $0 ▲ | $0 ▲ |
Ticket Service Segment | $0 ▲ | $0 ▲ |
5-Year Trend Analysis
A comprehensive look at SCWorx Corp.'s financial evolution and strategic trajectory over the past five years.
Key positives include a specialized SaaS offering that targets a real and costly pain point for hospitals—data fragmentation and supply chain inefficiency. The company demonstrates a workable gross margin structure, strong short-term liquidity, low traditional debt, and a net cash position. Its product strategy, centered on a comprehensive, interoperable data platform with modular components, provides a clear narrative and potential for sticky customer relationships. These elements together give SCWorx a foundation for potential growth if it can execute commercially and operationally.
The most important risks are financial: substantial operating and net losses, negative cash flow from operations, and reliance on external financing to grow or even maintain operations. Deeply negative retained earnings and an asset base dominated by goodwill and other intangibles highlight a history of losses and potential vulnerability to future write-downs. Competitive risks are also significant, given the presence of much larger healthcare IT players and the company’s small scale and limited brand recognition. If revenue growth does not accelerate or costs are not meaningfully reduced, the current model may prove difficult to sustain over time.
Looking ahead, SCWorx’s outlook hinges on its ability to translate its specialized technology and data platform into a broader, more profitable customer base before financial flexibility tightens. The strong liquidity position buys some time, but ongoing cash burn and high financing costs create pressure to show operational improvement. In a favorable scenario, increased adoption, better cost control, and deeper partnerships could gradually move the company toward a self-sustaining model. In a less favorable scenario, continued losses and competitive headwinds could force strategic changes, restructurings, or additional capital raises under potentially less attractive terms. Overall, the future path remains uncertain and will be driven primarily by execution, customer traction, and cost discipline.

CEO
Timothy Andrew Hannibal
Compensation Summary
(Year 2024)
Upcoming Earnings
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2026-04-10 | Reverse | 1:15 |
| 2023-10-11 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
Summary
Showing Top 1 of 1

